Design and Development of Solid Lipid Nanoparticles to enhance the oral absorbability of poorly soluble drugs in the special preference of Antihyperlipidemic drugs
Solid lipid nanoparticles, hyperlipidemia, simvastatin, NDDS.
Evidently, oral delivery is recommended as the most practical drug administration method due to its many benefits over other delivery methods, including the absence of pain perception, ease of self-administration, and great patient compliance. The large array of commercially available medications are often given orally all over the world. The effectiveness of these medications depends on their oral absorbability, which in turn depends mostly on the physiological makeup of the gut and pharmacological characteristics. Drugs' ability to cross GI barriers is negatively impacted by several of its unfavourable properties, including poor hydrophobicity, low permeability, chemical instability, and excessive first-pass metabolism. The GI tract has membrane barriers that are biological, chemical, enzymatic, and physical that prevent poorly absorbed medications from being transported and working as intended. As a result, encapsulating the drug in and allowing it to absorb on the surface of the nanocarrier systems is one of the most promising methods for improving the absorption of these medications. These nanosystems serve as an intelligent means of transferring insoluble and poorly permeable compounds over obstacles. They could alter the way that medications loaded on nanoparticles move across membranes, thereby enhancing their ability to diffuse over obstacles in the intestinal mucosa. As an efficient replacement carrier to the conventional colloidal techniques, such as liposomes and polymeric particles, solid lipid nanoparticles (SLNs), a novel nanosized drug delivery technology, have been attracting increased interest. Solid lipid nanoparticles gaining interest in delivery of drugs which finds hurdles in absorption due to low solubility and poor oral absorption. The current investigations' goal was to use a novel lipid-based formulation called solid lipid nanoparticles to increase the oral bioavailability of a model medication from the antihyperlipidemic therapeutic category. The solid lipid nanoparticle may improve medicine oral bioavailability by bypassing the hepatic metabolism of the drug, increasing permeability through the lymphatic pathway.
"Design and Development of Solid Lipid Nanoparticles to enhance the oral absorbability of poorly soluble drugs in the special preference of Antihyperlipidemic drugs", IJSDR - International Journal of Scientific Development and Research (www.IJSDR.org), ISSN:2455-2631, Vol.9, Issue 2, page no.868 - 875, February-2024, Available :https://ijsdr.org/papers/IJSDR2402126.pdf
Volume 9
Issue 2,
February-2024
Pages : 868 - 875
Paper Reg. ID: IJSDR_210401
Published Paper Id: IJSDR2402126
Downloads: 000347304
Research Area: Other
Country: -, -, India
ISSN: 2455-2631 | IMPACT FACTOR: 9.15 Calculated By Google Scholar | ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 9.15 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Publisher: IJSDR(IJ Publication) Janvi Wave
